nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP2C8—Vismodegib—skin cancer	0.124	0.187	CbGbCtD
Triazolam—CYP2C9—Vismodegib—skin cancer	0.0866	0.131	CbGbCtD
Triazolam—CYP3A4—Imiquimod—skin cancer	0.0727	0.11	CbGbCtD
Triazolam—CYP3A4—Temozolomide—skin cancer	0.0727	0.11	CbGbCtD
Triazolam—CYP3A4—Vismodegib—skin cancer	0.0504	0.0759	CbGbCtD
Triazolam—CYP3A7—Docetaxel—skin cancer	0.0467	0.0704	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0467	0.0704	CbGbCtD
Triazolam—CYP2C8—Fluorouracil—skin cancer	0.0441	0.0665	CbGbCtD
Triazolam—CYP3A4—Vemurafenib—skin cancer	0.0398	0.06	CbGbCtD
Triazolam—CYP3A5—Docetaxel—skin cancer	0.035	0.0528	CbGbCtD
Triazolam—CYP2C9—Fluorouracil—skin cancer	0.0308	0.0464	CbGbCtD
Triazolam—CYP3A4—Docetaxel—skin cancer	0.0137	0.0206	CbGbCtD
Triazolam—GABRR3—nerve—skin cancer	0.00876	0.0765	CbGeAlD
Triazolam—GABRQ—nerve—skin cancer	0.00876	0.0765	CbGeAlD
Triazolam—GABRR2—nerve—skin cancer	0.0076	0.0663	CbGeAlD
Triazolam—GABRR1—nerve—skin cancer	0.00731	0.0638	CbGeAlD
Triazolam—TSPO—hindlimb—skin cancer	0.00623	0.0544	CbGeAlD
Triazolam—TSPO—appendage—skin cancer	0.00534	0.0466	CbGeAlD
Triazolam—Dysaesthesia—Fluorouracil—skin cancer	0.00388	0.0174	CcSEcCtD
Triazolam—Slurred speech—Fluorouracil—skin cancer	0.00375	0.0169	CcSEcCtD
Triazolam—GABRE—hair follicle—skin cancer	0.0034	0.0296	CbGeAlD
Triazolam—TSPO—hair follicle—skin cancer	0.00317	0.0277	CbGeAlD
Triazolam—GABRA3—neck—skin cancer	0.00309	0.0269	CbGeAlD
Triazolam—GABRP—nipple—skin cancer	0.00302	0.0263	CbGeAlD
Triazolam—TSPO—blood vessel—skin cancer	0.00297	0.026	CbGeAlD
Triazolam—Dysaesthesia—Docetaxel—skin cancer	0.0028	0.0126	CcSEcCtD
Triazolam—Dysgeusia—Vismodegib—skin cancer	0.00247	0.0111	CcSEcCtD
Triazolam—Aggression—Bleomycin—skin cancer	0.00246	0.011	CcSEcCtD
Triazolam—Muscle spasms—Vismodegib—skin cancer	0.00242	0.0109	CcSEcCtD
Triazolam—Memory impairment—Temozolomide—skin cancer	0.00232	0.0104	CcSEcCtD
Triazolam—GABRE—nipple—skin cancer	0.0023	0.0201	CbGeAlD
Triazolam—Menstruation irregular—Docetaxel—skin cancer	0.00219	0.00984	CcSEcCtD
Triazolam—TSPO—nipple—skin cancer	0.00215	0.0188	CbGeAlD
Triazolam—TSPO—neck—skin cancer	0.00213	0.0186	CbGeAlD
Triazolam—Irritability—Imiquimod—skin cancer	0.0021	0.00947	CcSEcCtD
Triazolam—Urinary retention—Imiquimod—skin cancer	0.0021	0.00943	CcSEcCtD
Triazolam—GABRQ—head—skin cancer	0.00208	0.0181	CbGeAlD
Triazolam—GABRR3—head—skin cancer	0.00208	0.0181	CbGeAlD
Triazolam—Eye irritation—Fluorouracil—skin cancer	0.00196	0.00884	CcSEcCtD
Triazolam—Hearing impaired—Temozolomide—skin cancer	0.00191	0.0086	CcSEcCtD
Triazolam—Sweating increased—Imiquimod—skin cancer	0.00186	0.00835	CcSEcCtD
Triazolam—Coordination abnormal—Temozolomide—skin cancer	0.00185	0.00834	CcSEcCtD
Triazolam—GABRG3—head—skin cancer	0.00182	0.0159	CbGeAlD
Triazolam—GABRR2—head—skin cancer	0.0018	0.0157	CbGeAlD
Triazolam—Redness—Docetaxel—skin cancer	0.00179	0.00807	CcSEcCtD
Triazolam—Decreased appetite—Vismodegib—skin cancer	0.00179	0.00804	CcSEcCtD
Triazolam—Dysuria—Imiquimod—skin cancer	0.00178	0.00802	CcSEcCtD
Triazolam—GABRA4—mammalian vulva—skin cancer	0.00177	0.0155	CbGeAlD
Triazolam—Fatigue—Vismodegib—skin cancer	0.00177	0.00798	CcSEcCtD
Triazolam—Dysarthria—Fluorouracil—skin cancer	0.00177	0.00798	CcSEcCtD
Triazolam—Pain—Vismodegib—skin cancer	0.00176	0.00791	CcSEcCtD
Triazolam—Constipation—Vismodegib—skin cancer	0.00176	0.00791	CcSEcCtD
Triazolam—Depressed level of consciousness—Temozolomide—skin cancer	0.00176	0.00791	CcSEcCtD
Triazolam—Disorientation—Bleomycin—skin cancer	0.00175	0.00788	CcSEcCtD
Triazolam—GABRR1—head—skin cancer	0.00173	0.0151	CbGeAlD
Triazolam—Gastrointestinal pain—Vismodegib—skin cancer	0.00168	0.00757	CcSEcCtD
Triazolam—Abdominal pain—Vismodegib—skin cancer	0.00163	0.00731	CcSEcCtD
Triazolam—Hepatic failure—Dactinomycin—skin cancer	0.00163	0.00731	CcSEcCtD
Triazolam—Mental disability—Temozolomide—skin cancer	0.00158	0.00711	CcSEcCtD
Triazolam—Erythema—Vemurafenib—skin cancer	0.00156	0.007	CcSEcCtD
Triazolam—TSPO—connective tissue—skin cancer	0.00152	0.0133	CbGeAlD
Triazolam—Dysgeusia—Vemurafenib—skin cancer	0.00152	0.00686	CcSEcCtD
Triazolam—GABRP—female reproductive system—skin cancer	0.00151	0.0132	CbGeAlD
Triazolam—GABRD—head—skin cancer	0.00151	0.0132	CbGeAlD
Triazolam—Deafness—Temozolomide—skin cancer	0.00148	0.00664	CcSEcCtD
Triazolam—Asthenia—Vismodegib—skin cancer	0.00148	0.00664	CcSEcCtD
Triazolam—Hepatic failure—Temozolomide—skin cancer	0.00147	0.00661	CcSEcCtD
Triazolam—Visual impairment—Imiquimod—skin cancer	0.00147	0.00661	CcSEcCtD
Triazolam—Pruritus—Vismodegib—skin cancer	0.00145	0.00655	CcSEcCtD
Triazolam—GABRG1—head—skin cancer	0.00145	0.0127	CbGeAlD
Triazolam—TSPO—epithelium—skin cancer	0.00145	0.0126	CbGeAlD
Triazolam—GABRA6—head—skin cancer	0.00144	0.0126	CbGeAlD
Triazolam—Euphoric mood—Fluorouracil—skin cancer	0.00144	0.00648	CcSEcCtD
Triazolam—Tinnitus—Imiquimod—skin cancer	0.00142	0.0064	CcSEcCtD
Triazolam—Eye irritation—Docetaxel—skin cancer	0.00142	0.00638	CcSEcCtD
Triazolam—Diarrhoea—Vismodegib—skin cancer	0.00141	0.00633	CcSEcCtD
Triazolam—GABRB1—head—skin cancer	0.00141	0.0123	CbGeAlD
Triazolam—Amnesia—Temozolomide—skin cancer	0.00141	0.00633	CcSEcCtD
Triazolam—GABRA5—head—skin cancer	0.0014	0.0122	CbGeAlD
Triazolam—GABRB3—connective tissue—skin cancer	0.00138	0.0121	CbGeAlD
Triazolam—TSPO—skin of body—skin cancer	0.00138	0.012	CbGeAlD
Triazolam—Disorientation—Fluorouracil—skin cancer	0.00136	0.00612	CcSEcCtD
Triazolam—GABRE—mammalian vulva—skin cancer	0.00134	0.0117	CbGeAlD
Triazolam—Erythema—Imiquimod—skin cancer	0.00133	0.00597	CcSEcCtD
Triazolam—Vomiting—Vismodegib—skin cancer	0.00131	0.00588	CcSEcCtD
Triazolam—GABRA3—head—skin cancer	0.0013	0.0114	CbGeAlD
Triazolam—Affect lability—Temozolomide—skin cancer	0.0013	0.00585	CcSEcCtD
Triazolam—Amnesia—Fluorouracil—skin cancer	0.0013	0.00583	CcSEcCtD
Triazolam—Dermatitis—Vismodegib—skin cancer	0.0013	0.00583	CcSEcCtD
Triazolam—Hearing impaired—Docetaxel—skin cancer	0.00127	0.00572	CcSEcCtD
Triazolam—GABRA4—head—skin cancer	0.00127	0.0111	CbGeAlD
Triazolam—GABRR2—lymph node—skin cancer	0.00126	0.011	CbGeAlD
Triazolam—GABRP—head—skin cancer	0.00126	0.011	CbGeAlD
Triazolam—TSPO—mammalian vulva—skin cancer	0.00126	0.011	CbGeAlD
Triazolam—Mood swings—Temozolomide—skin cancer	0.00125	0.00563	CcSEcCtD
Triazolam—Ataxia—Temozolomide—skin cancer	0.00124	0.00559	CcSEcCtD
Triazolam—Ill-defined disorder—Imiquimod—skin cancer	0.00123	0.00554	CcSEcCtD
Triazolam—Nausea—Vismodegib—skin cancer	0.00122	0.0055	CcSEcCtD
Triazolam—Agitation—Imiquimod—skin cancer	0.00122	0.00549	CcSEcCtD
Triazolam—Osteoarthritis—Fluorouracil—skin cancer	0.00122	0.00548	CcSEcCtD
Triazolam—Malaise—Imiquimod—skin cancer	0.0012	0.00539	CcSEcCtD
Triazolam—Syncope—Imiquimod—skin cancer	0.00119	0.00536	CcSEcCtD
Triazolam—Stomatitis—Bleomycin—skin cancer	0.00118	0.00529	CcSEcCtD
Triazolam—Palpitations—Imiquimod—skin cancer	0.00117	0.00528	CcSEcCtD
Triazolam—Loss of consciousness—Imiquimod—skin cancer	0.00117	0.00525	CcSEcCtD
Triazolam—Muscular weakness—Temozolomide—skin cancer	0.00117	0.00524	CcSEcCtD
Triazolam—Irritability—Fluorouracil—skin cancer	0.00116	0.00523	CcSEcCtD
Triazolam—GABRE—female reproductive system—skin cancer	0.00115	0.0101	CbGeAlD
Triazolam—Hypertension—Imiquimod—skin cancer	0.00115	0.00516	CcSEcCtD
Triazolam—Ataxia—Fluorouracil—skin cancer	0.00114	0.00515	CcSEcCtD
Triazolam—Chest pain—Imiquimod—skin cancer	0.00113	0.00509	CcSEcCtD
Triazolam—Anxiety—Imiquimod—skin cancer	0.00113	0.00507	CcSEcCtD
Triazolam—Discomfort—Imiquimod—skin cancer	0.00112	0.00502	CcSEcCtD
Triazolam—TSPO—lymphoid tissue—skin cancer	0.00111	0.00973	CbGeAlD
Triazolam—Sweating increased—Temozolomide—skin cancer	0.00111	0.005	CcSEcCtD
Triazolam—Dry mouth—Imiquimod—skin cancer	0.00111	0.00497	CcSEcCtD
Triazolam—Decreased appetite—Vemurafenib—skin cancer	0.0011	0.00497	CcSEcCtD
Triazolam—Stomatitis—Dactinomycin—skin cancer	0.0011	0.00494	CcSEcCtD
Triazolam—Fatigue—Vemurafenib—skin cancer	0.0011	0.00493	CcSEcCtD
Triazolam—Constipation—Vemurafenib—skin cancer	0.00109	0.00489	CcSEcCtD
Triazolam—Oedema—Imiquimod—skin cancer	0.00108	0.00487	CcSEcCtD
Triazolam—Lightheadedness—Docetaxel—skin cancer	0.00108	0.00487	CcSEcCtD
Triazolam—TSPO—female reproductive system—skin cancer	0.00108	0.00939	CbGeAlD
Triazolam—Muscular weakness—Fluorouracil—skin cancer	0.00107	0.00483	CcSEcCtD
Triazolam—Dysuria—Temozolomide—skin cancer	0.00107	0.0048	CcSEcCtD
Triazolam—Shock—Imiquimod—skin cancer	0.00107	0.0048	CcSEcCtD
Triazolam—GABRG2—head—skin cancer	0.00106	0.00927	CbGeAlD
Triazolam—GABRB2—head—skin cancer	0.00106	0.00927	CbGeAlD
Triazolam—Tachycardia—Imiquimod—skin cancer	0.00106	0.00476	CcSEcCtD
Triazolam—Hyperhidrosis—Imiquimod—skin cancer	0.00105	0.00471	CcSEcCtD
Triazolam—Anorexia—Imiquimod—skin cancer	0.00103	0.00465	CcSEcCtD
Triazolam—Stomatitis—Temozolomide—skin cancer	0.000992	0.00446	CcSEcCtD
Triazolam—Deafness—Docetaxel—skin cancer	0.000982	0.00442	CcSEcCtD
Triazolam—Insomnia—Imiquimod—skin cancer	0.00098	0.00441	CcSEcCtD
Triazolam—Hepatic failure—Docetaxel—skin cancer	0.000978	0.0044	CcSEcCtD
Triazolam—GABRB3—female reproductive system—skin cancer	0.000976	0.00852	CbGeAlD
Triazolam—Paraesthesia—Imiquimod—skin cancer	0.000973	0.00438	CcSEcCtD
Triazolam—GABRA2—head—skin cancer	0.00097	0.00847	CbGeAlD
Triazolam—Dyspnoea—Imiquimod—skin cancer	0.000966	0.00435	CcSEcCtD
Triazolam—Somnolence—Imiquimod—skin cancer	0.000963	0.00433	CcSEcCtD
Triazolam—GABRE—head—skin cancer	0.000962	0.0084	CbGeAlD
Triazolam—Erythema—Bleomycin—skin cancer	0.000943	0.00424	CcSEcCtD
Triazolam—Decreased appetite—Imiquimod—skin cancer	0.000942	0.00424	CcSEcCtD
Triazolam—GABRA1—head—skin cancer	0.000938	0.00819	CbGeAlD
Triazolam—Hypersensitivity—Vemurafenib—skin cancer	0.000936	0.00421	CcSEcCtD
Triazolam—Fatigue—Imiquimod—skin cancer	0.000934	0.0042	CcSEcCtD
Triazolam—Visual disturbance—Docetaxel—skin cancer	0.000927	0.00417	CcSEcCtD
Triazolam—Pain—Imiquimod—skin cancer	0.000927	0.00417	CcSEcCtD
Triazolam—Stomatitis—Fluorouracil—skin cancer	0.000914	0.00411	CcSEcCtD
Triazolam—Asthenia—Vemurafenib—skin cancer	0.000912	0.0041	CcSEcCtD
Triazolam—Hallucination—Temozolomide—skin cancer	0.000909	0.00409	CcSEcCtD
Triazolam—Pruritus—Vemurafenib—skin cancer	0.000899	0.00404	CcSEcCtD
Triazolam—TSPO—head—skin cancer	0.000898	0.00784	CbGeAlD
Triazolam—Feeling abnormal—Imiquimod—skin cancer	0.000893	0.00402	CcSEcCtD
Triazolam—Gastrointestinal pain—Imiquimod—skin cancer	0.000886	0.00399	CcSEcCtD
Triazolam—Visual impairment—Temozolomide—skin cancer	0.000881	0.00396	CcSEcCtD
Triazolam—Erythema—Dactinomycin—skin cancer	0.00088	0.00396	CcSEcCtD
Triazolam—Ill-defined disorder—Bleomycin—skin cancer	0.000875	0.00394	CcSEcCtD
Triazolam—Diarrhoea—Vemurafenib—skin cancer	0.000869	0.00391	CcSEcCtD
Triazolam—Abdominal pain—Imiquimod—skin cancer	0.000857	0.00385	CcSEcCtD
Triazolam—Tinnitus—Temozolomide—skin cancer	0.000852	0.00383	CcSEcCtD
Triazolam—Malaise—Bleomycin—skin cancer	0.000851	0.00383	CcSEcCtD
Triazolam—Dizziness—Vemurafenib—skin cancer	0.00084	0.00378	CcSEcCtD
Triazolam—Ataxia—Docetaxel—skin cancer	0.000826	0.00372	CcSEcCtD
Triazolam—Ill-defined disorder—Dactinomycin—skin cancer	0.000816	0.00367	CcSEcCtD
Triazolam—GABRB3—head—skin cancer	0.000816	0.00712	CbGeAlD
Triazolam—Vomiting—Vemurafenib—skin cancer	0.000808	0.00363	CcSEcCtD
Triazolam—Chest pain—Bleomycin—skin cancer	0.000803	0.00361	CcSEcCtD
Triazolam—Dermatitis—Vemurafenib—skin cancer	0.0008	0.0036	CcSEcCtD
Triazolam—Hypersensitivity—Imiquimod—skin cancer	0.000798	0.00359	CcSEcCtD
Triazolam—Headache—Vemurafenib—skin cancer	0.000796	0.00358	CcSEcCtD
Triazolam—Erythema—Temozolomide—skin cancer	0.000796	0.00358	CcSEcCtD
Triazolam—Discomfort—Bleomycin—skin cancer	0.000793	0.00357	CcSEcCtD
Triazolam—Malaise—Dactinomycin—skin cancer	0.000793	0.00357	CcSEcCtD
Triazolam—Cramp muscle—Docetaxel—skin cancer	0.000791	0.00356	CcSEcCtD
Triazolam—Dysgeusia—Temozolomide—skin cancer	0.000779	0.00351	CcSEcCtD
Triazolam—Asthenia—Imiquimod—skin cancer	0.000777	0.0035	CcSEcCtD
Triazolam—Confusional state—Bleomycin—skin cancer	0.000776	0.00349	CcSEcCtD
Triazolam—Oedema—Bleomycin—skin cancer	0.00077	0.00346	CcSEcCtD
Triazolam—Pruritus—Imiquimod—skin cancer	0.000767	0.00345	CcSEcCtD
Triazolam—Nausea—Vemurafenib—skin cancer	0.000755	0.0034	CcSEcCtD
Triazolam—Tremor—Temozolomide—skin cancer	0.000745	0.00335	CcSEcCtD
Triazolam—Diarrhoea—Imiquimod—skin cancer	0.000741	0.00334	CcSEcCtD
Triazolam—Discomfort—Dactinomycin—skin cancer	0.00074	0.00333	CcSEcCtD
Triazolam—Ill-defined disorder—Temozolomide—skin cancer	0.000738	0.00332	CcSEcCtD
Triazolam—CYP2C8—female reproductive system—skin cancer	0.000738	0.00644	CbGeAlD
Triazolam—Anorexia—Bleomycin—skin cancer	0.000734	0.0033	CcSEcCtD
Triazolam—Erythema—Fluorouracil—skin cancer	0.000733	0.0033	CcSEcCtD
Triazolam—Agitation—Temozolomide—skin cancer	0.000731	0.00329	CcSEcCtD
Triazolam—Oedema—Dactinomycin—skin cancer	0.000718	0.00323	CcSEcCtD
Triazolam—Malaise—Temozolomide—skin cancer	0.000717	0.00323	CcSEcCtD
Triazolam—Dizziness—Imiquimod—skin cancer	0.000717	0.00322	CcSEcCtD
Triazolam—Palpitations—Temozolomide—skin cancer	0.000703	0.00316	CcSEcCtD
Triazolam—Paraesthesia—Bleomycin—skin cancer	0.000691	0.00311	CcSEcCtD
Triazolam—Vomiting—Imiquimod—skin cancer	0.000689	0.0031	CcSEcCtD
Triazolam—Hypertension—Temozolomide—skin cancer	0.000687	0.00309	CcSEcCtD
Triazolam—Dyspnoea—Bleomycin—skin cancer	0.000686	0.00309	CcSEcCtD
Triazolam—Anorexia—Dactinomycin—skin cancer	0.000684	0.00308	CcSEcCtD
Triazolam—Dermatitis—Imiquimod—skin cancer	0.000683	0.00307	CcSEcCtD
Triazolam—GABRA2—lymph node—skin cancer	0.000679	0.00593	CbGeAlD
Triazolam—Headache—Imiquimod—skin cancer	0.000679	0.00305	CcSEcCtD
Triazolam—Anxiety—Temozolomide—skin cancer	0.000675	0.00304	CcSEcCtD
Triazolam—GABRE—lymph node—skin cancer	0.000674	0.00588	CbGeAlD
Triazolam—Discomfort—Temozolomide—skin cancer	0.000669	0.00301	CcSEcCtD
Triazolam—Decreased appetite—Bleomycin—skin cancer	0.000669	0.00301	CcSEcCtD
Triazolam—Dry mouth—Temozolomide—skin cancer	0.000662	0.00298	CcSEcCtD
Triazolam—Stomatitis—Docetaxel—skin cancer	0.00066	0.00297	CcSEcCtD
Triazolam—Jaundice—Docetaxel—skin cancer	0.00066	0.00297	CcSEcCtD
Triazolam—Pain—Bleomycin—skin cancer	0.000658	0.00296	CcSEcCtD
Triazolam—CYP2C9—female reproductive system—skin cancer	0.000655	0.00572	CbGeAlD
Triazolam—Confusional state—Temozolomide—skin cancer	0.000655	0.00295	CcSEcCtD
Triazolam—Oedema—Temozolomide—skin cancer	0.000649	0.00292	CcSEcCtD
Triazolam—Nausea—Imiquimod—skin cancer	0.000644	0.0029	CcSEcCtD
Triazolam—Feeling abnormal—Bleomycin—skin cancer	0.000634	0.00285	CcSEcCtD
Triazolam—TSPO—lymph node—skin cancer	0.000629	0.00549	CbGeAlD
Triazolam—Hyperhidrosis—Temozolomide—skin cancer	0.000628	0.00282	CcSEcCtD
Triazolam—Chest pain—Fluorouracil—skin cancer	0.000624	0.00281	CcSEcCtD
Triazolam—Decreased appetite—Dactinomycin—skin cancer	0.000624	0.00281	CcSEcCtD
Triazolam—Fatigue—Dactinomycin—skin cancer	0.000619	0.00278	CcSEcCtD
Triazolam—Anorexia—Temozolomide—skin cancer	0.000619	0.00278	CcSEcCtD
Triazolam—Discomfort—Fluorouracil—skin cancer	0.000617	0.00277	CcSEcCtD
Triazolam—Pain—Dactinomycin—skin cancer	0.000614	0.00276	CcSEcCtD
Triazolam—Confusional state—Fluorouracil—skin cancer	0.000603	0.00271	CcSEcCtD
Triazolam—Oedema—Fluorouracil—skin cancer	0.000598	0.00269	CcSEcCtD
Triazolam—Feeling abnormal—Dactinomycin—skin cancer	0.000592	0.00266	CcSEcCtD
Triazolam—Insomnia—Temozolomide—skin cancer	0.000587	0.00264	CcSEcCtD
Triazolam—Gastrointestinal pain—Dactinomycin—skin cancer	0.000587	0.00264	CcSEcCtD
Triazolam—Visual impairment—Docetaxel—skin cancer	0.000586	0.00264	CcSEcCtD
Triazolam—Tachycardia—Fluorouracil—skin cancer	0.000584	0.00263	CcSEcCtD
Triazolam—Paraesthesia—Temozolomide—skin cancer	0.000583	0.00262	CcSEcCtD
Triazolam—Dyspnoea—Temozolomide—skin cancer	0.000579	0.0026	CcSEcCtD
Triazolam—Somnolence—Temozolomide—skin cancer	0.000577	0.0026	CcSEcCtD
Triazolam—Anorexia—Fluorouracil—skin cancer	0.00057	0.00257	CcSEcCtD
Triazolam—Abdominal pain—Dactinomycin—skin cancer	0.000568	0.00255	CcSEcCtD
Triazolam—Hypersensitivity—Bleomycin—skin cancer	0.000567	0.00255	CcSEcCtD
Triazolam—Decreased appetite—Temozolomide—skin cancer	0.000564	0.00254	CcSEcCtD
Triazolam—Fatigue—Temozolomide—skin cancer	0.00056	0.00252	CcSEcCtD
Triazolam—Pain—Temozolomide—skin cancer	0.000555	0.0025	CcSEcCtD
Triazolam—Constipation—Temozolomide—skin cancer	0.000555	0.0025	CcSEcCtD
Triazolam—Asthenia—Bleomycin—skin cancer	0.000552	0.00248	CcSEcCtD
Triazolam—Pruritus—Bleomycin—skin cancer	0.000545	0.00245	CcSEcCtD
Triazolam—Insomnia—Fluorouracil—skin cancer	0.000541	0.00243	CcSEcCtD
Triazolam—Paraesthesia—Fluorouracil—skin cancer	0.000537	0.00242	CcSEcCtD
Triazolam—Feeling abnormal—Temozolomide—skin cancer	0.000535	0.00241	CcSEcCtD
Triazolam—Dyspnoea—Fluorouracil—skin cancer	0.000533	0.0024	CcSEcCtD
Triazolam—Somnolence—Fluorouracil—skin cancer	0.000532	0.00239	CcSEcCtD
Triazolam—Gastrointestinal pain—Temozolomide—skin cancer	0.000531	0.00239	CcSEcCtD
Triazolam—Erythema—Docetaxel—skin cancer	0.000529	0.00238	CcSEcCtD
Triazolam—Hypersensitivity—Dactinomycin—skin cancer	0.000529	0.00238	CcSEcCtD
Triazolam—Decreased appetite—Fluorouracil—skin cancer	0.00052	0.00234	CcSEcCtD
Triazolam—Dysgeusia—Docetaxel—skin cancer	0.000518	0.00233	CcSEcCtD
Triazolam—Asthenia—Dactinomycin—skin cancer	0.000515	0.00232	CcSEcCtD
Triazolam—Abdominal pain—Temozolomide—skin cancer	0.000513	0.00231	CcSEcCtD
Triazolam—Pain—Fluorouracil—skin cancer	0.000512	0.0023	CcSEcCtD
Triazolam—Muscle spasms—Docetaxel—skin cancer	0.000509	0.00229	CcSEcCtD
Triazolam—CYP3A4—female reproductive system—skin cancer	0.0005	0.00436	CbGeAlD
Triazolam—Feeling abnormal—Fluorouracil—skin cancer	0.000493	0.00222	CcSEcCtD
Triazolam—Diarrhoea—Dactinomycin—skin cancer	0.000491	0.00221	CcSEcCtD
Triazolam—Vomiting—Bleomycin—skin cancer	0.000489	0.0022	CcSEcCtD
Triazolam—Dermatitis—Bleomycin—skin cancer	0.000485	0.00218	CcSEcCtD
Triazolam—Hypersensitivity—Temozolomide—skin cancer	0.000478	0.00215	CcSEcCtD
Triazolam—Syncope—Docetaxel—skin cancer	0.000474	0.00213	CcSEcCtD
Triazolam—Palpitations—Docetaxel—skin cancer	0.000468	0.0021	CcSEcCtD
Triazolam—Asthenia—Temozolomide—skin cancer	0.000466	0.0021	CcSEcCtD
Triazolam—Loss of consciousness—Docetaxel—skin cancer	0.000465	0.00209	CcSEcCtD
Triazolam—Pruritus—Temozolomide—skin cancer	0.000459	0.00207	CcSEcCtD
Triazolam—Nausea—Bleomycin—skin cancer	0.000457	0.00206	CcSEcCtD
Triazolam—Hypertension—Docetaxel—skin cancer	0.000457	0.00206	CcSEcCtD
Triazolam—Vomiting—Dactinomycin—skin cancer	0.000456	0.00205	CcSEcCtD
Triazolam—Chest pain—Docetaxel—skin cancer	0.00045	0.00203	CcSEcCtD
Triazolam—Diarrhoea—Temozolomide—skin cancer	0.000444	0.002	CcSEcCtD
Triazolam—Hypersensitivity—Fluorouracil—skin cancer	0.000441	0.00198	CcSEcCtD
Triazolam—Dry mouth—Docetaxel—skin cancer	0.000441	0.00198	CcSEcCtD
Triazolam—Confusional state—Docetaxel—skin cancer	0.000435	0.00196	CcSEcCtD
Triazolam—Oedema—Docetaxel—skin cancer	0.000432	0.00194	CcSEcCtD
Triazolam—Dizziness—Temozolomide—skin cancer	0.000429	0.00193	CcSEcCtD
Triazolam—Nausea—Dactinomycin—skin cancer	0.000426	0.00192	CcSEcCtD
Triazolam—Shock—Docetaxel—skin cancer	0.000425	0.00191	CcSEcCtD
Triazolam—Pruritus—Fluorouracil—skin cancer	0.000423	0.0019	CcSEcCtD
Triazolam—Tachycardia—Docetaxel—skin cancer	0.000421	0.0019	CcSEcCtD
Triazolam—Vomiting—Temozolomide—skin cancer	0.000413	0.00186	CcSEcCtD
Triazolam—Anorexia—Docetaxel—skin cancer	0.000412	0.00185	CcSEcCtD
Triazolam—Diarrhoea—Fluorouracil—skin cancer	0.000409	0.00184	CcSEcCtD
Triazolam—Dermatitis—Temozolomide—skin cancer	0.000409	0.00184	CcSEcCtD
Triazolam—Headache—Temozolomide—skin cancer	0.000407	0.00183	CcSEcCtD
Triazolam—Dizziness—Fluorouracil—skin cancer	0.000396	0.00178	CcSEcCtD
Triazolam—Insomnia—Docetaxel—skin cancer	0.000391	0.00176	CcSEcCtD
Triazolam—Paraesthesia—Docetaxel—skin cancer	0.000388	0.00174	CcSEcCtD
Triazolam—Nausea—Temozolomide—skin cancer	0.000386	0.00174	CcSEcCtD
Triazolam—Dyspnoea—Docetaxel—skin cancer	0.000385	0.00173	CcSEcCtD
Triazolam—Somnolence—Docetaxel—skin cancer	0.000384	0.00173	CcSEcCtD
Triazolam—Vomiting—Fluorouracil—skin cancer	0.00038	0.00171	CcSEcCtD
Triazolam—Dermatitis—Fluorouracil—skin cancer	0.000377	0.0017	CcSEcCtD
Triazolam—Decreased appetite—Docetaxel—skin cancer	0.000375	0.00169	CcSEcCtD
Triazolam—Headache—Fluorouracil—skin cancer	0.000375	0.00169	CcSEcCtD
Triazolam—Fatigue—Docetaxel—skin cancer	0.000372	0.00167	CcSEcCtD
Triazolam—Pain—Docetaxel—skin cancer	0.000369	0.00166	CcSEcCtD
Triazolam—Constipation—Docetaxel—skin cancer	0.000369	0.00166	CcSEcCtD
Triazolam—Feeling abnormal—Docetaxel—skin cancer	0.000356	0.0016	CcSEcCtD
Triazolam—Nausea—Fluorouracil—skin cancer	0.000355	0.0016	CcSEcCtD
Triazolam—Gastrointestinal pain—Docetaxel—skin cancer	0.000353	0.00159	CcSEcCtD
Triazolam—Abdominal pain—Docetaxel—skin cancer	0.000341	0.00154	CcSEcCtD
Triazolam—Hypersensitivity—Docetaxel—skin cancer	0.000318	0.00143	CcSEcCtD
Triazolam—Asthenia—Docetaxel—skin cancer	0.00031	0.00139	CcSEcCtD
Triazolam—Pruritus—Docetaxel—skin cancer	0.000306	0.00137	CcSEcCtD
Triazolam—Diarrhoea—Docetaxel—skin cancer	0.000295	0.00133	CcSEcCtD
Triazolam—Dizziness—Docetaxel—skin cancer	0.000286	0.00128	CcSEcCtD
Triazolam—Vomiting—Docetaxel—skin cancer	0.000275	0.00124	CcSEcCtD
Triazolam—Dermatitis—Docetaxel—skin cancer	0.000272	0.00122	CcSEcCtD
Triazolam—Headache—Docetaxel—skin cancer	0.000271	0.00122	CcSEcCtD
Triazolam—Nausea—Docetaxel—skin cancer	0.000256	0.00115	CcSEcCtD
